TWI788343B - 治療用化合物 - Google Patents

治療用化合物 Download PDF

Info

Publication number
TWI788343B
TWI788343B TW107113171A TW107113171A TWI788343B TW I788343 B TWI788343 B TW I788343B TW 107113171 A TW107113171 A TW 107113171A TW 107113171 A TW107113171 A TW 107113171A TW I788343 B TWI788343 B TW I788343B
Authority
TW
Taiwan
Prior art keywords
methyl
pyrazol
oxo
pyridin
img
Prior art date
Application number
TW107113171A
Other languages
English (en)
Chinese (zh)
Other versions
TW201841900A (zh
Inventor
萊尼 崔羅斯
胡安曼努爾 貝坦科特
陶費吉 甘努尼
麥可布雷南 華勒斯
阿莫克 柏盧爾
Original Assignee
美商塞爾基因定量細胞研究公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商塞爾基因定量細胞研究公司 filed Critical 美商塞爾基因定量細胞研究公司
Publication of TW201841900A publication Critical patent/TW201841900A/zh
Application granted granted Critical
Publication of TWI788343B publication Critical patent/TWI788343B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW107113171A 2017-04-18 2018-04-18 治療用化合物 TWI788343B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762486894P 2017-04-18 2017-04-18
US62/486,894 2017-04-18
US201862657456P 2018-04-13 2018-04-13
US62/657,456 2018-04-13

Publications (2)

Publication Number Publication Date
TW201841900A TW201841900A (zh) 2018-12-01
TWI788343B true TWI788343B (zh) 2023-01-01

Family

ID=63791349

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107113171A TWI788343B (zh) 2017-04-18 2018-04-18 治療用化合物
TW111146299A TW202332436A (zh) 2017-04-18 2018-04-18 治療用化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111146299A TW202332436A (zh) 2017-04-18 2018-04-18 治療用化合物

Country Status (5)

Country Link
US (4) US10617680B2 (https=)
EP (1) EP3612522A4 (https=)
JP (2) JP2020516672A (https=)
TW (2) TWI788343B (https=)
WO (1) WO2018195155A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018195155A1 (en) * 2017-04-18 2018-10-25 Celgene Quanticel Research, Inc. Therapeutic compounds
US10870648B2 (en) * 2018-06-29 2020-12-22 Forma Therapeutics, Inc. Inhibiting CREB binding protein (CBP)
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
TW202304303A (zh) * 2021-04-13 2023-02-01 美商富曼西公司 殺真菌之吡啶酮
CA3224302A1 (en) 2021-06-29 2023-01-05 Tay Therapeutics Limited Pyrrolopyridone derivatives useful in the treatment of cancer
WO2025010291A2 (en) * 2023-07-03 2025-01-09 The General Hospital Corporation Targeted epigenetic therapies for disorders of progranulin deficiency

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054434A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
US20130109652A1 (en) * 2004-09-17 2013-05-02 Addex Pharmaceuticals S.A. Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
WO2014055548A1 (en) * 2012-10-02 2014-04-10 Intermune, Inc. Anti-fibrotic pyridinones
WO2015058160A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406329A1 (de) * 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
CA2221692A1 (en) 1995-05-19 1996-11-21 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
JPH11508267A (ja) * 1995-06-26 1999-07-21 藤沢薬品工業株式会社 ピラゾール化合物および医薬組成物
JP3760957B2 (ja) * 1996-03-05 2006-03-29 信越化学工業株式会社 新規スルホニウム塩及び化学増幅ポジ型レジスト材料
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
AU2002306868A1 (en) * 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
EP1660087A2 (en) 2003-07-22 2006-05-31 Janssen Pharmaceutica N.V. Quinolinone derivatives as inhibitors of c-fms kinase
WO2005013982A1 (en) * 2003-08-06 2005-02-17 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
WO2005095384A1 (en) * 2004-04-01 2005-10-13 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JPWO2006137465A1 (ja) * 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
WO2007026950A1 (en) 2005-09-01 2007-03-08 Astellas Pharma Inc. Pyridazinone derivatives used for the treatment of pain
US7968572B2 (en) * 2005-10-03 2011-06-28 Ono Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
KR101352973B1 (ko) 2005-10-26 2014-01-22 삼성에스디아이 주식회사 연료전지용 탈황흡착제 및 이를 이용한 탈황방법
AU2007225273A1 (en) * 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
JP5182088B2 (ja) * 2006-04-19 2013-04-10 アステラス製薬株式会社 アゾールカルボキサミド誘導体
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
TW200906825A (en) 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
JPWO2009028543A1 (ja) 2007-08-30 2010-12-02 武田薬品工業株式会社 置換ピラゾール誘導体
BRPI0914772A2 (pt) * 2008-06-25 2015-10-20 Envivo Pharmaceuticals Inc compostos heterocíclicos 1,2-dissubstituídos
AP2011005824A0 (en) * 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
GB0919380D0 (en) * 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
ES2539170T3 (es) * 2010-01-12 2015-06-26 Ab Science Inhibidores de quinasas de oxazol
WO2012020786A1 (ja) 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
WO2012101654A2 (en) 2011-01-25 2012-08-02 Sphaera Pharma Pvt. Ltd Novel triazine compounds
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
US8809372B2 (en) * 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CN104470918A (zh) 2012-05-30 2015-03-25 日本新药株式会社 芳香族杂环衍生物及医药
AU2012382373A1 (en) 2012-06-12 2014-12-11 Abbvie Inc. Pyridinone and pyridazinone derivatives
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
BR112015022643A2 (pt) 2013-03-12 2017-07-18 Abbvie Inc inibidores diidro-pirrolpiridinona
US9670221B2 (en) 2013-03-14 2017-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Furopyridines as bromodomain inhibitors
JPWO2014157569A1 (ja) * 2013-03-28 2017-02-16 武田薬品工業株式会社 複素環化合物
JP6523251B2 (ja) 2013-05-01 2019-05-29 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃ−結合ヘテロシクロアルキル置換ピリミジン類及びそれらの用途
HUE041546T2 (hu) 2014-01-09 2019-05-28 Orion Corp Biciklusos heterociklusos származékvegyületek mint bromo doméninhibitorok
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
US10064869B2 (en) 2014-06-04 2018-09-04 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
CN106687445A (zh) * 2014-09-17 2017-05-17 维颂公司 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
CN108024971A (zh) * 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
JP2018524372A (ja) 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
US10201531B2 (en) * 2015-08-12 2019-02-12 Mochida Pharmaceutical Co., Ltd. Indazolyl-oxo-isothiazole compounds
ES2913048T3 (es) * 2015-09-21 2022-05-31 Opna Immuno Oncology Sa Compuestos heterocíclicos y usos de estos
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
KR102470130B1 (ko) 2016-07-18 2022-11-24 내셔널 인스티튜트 오브 바이올로지칼 사이언시스, 베이징 아폽토시스 억제제
WO2018195155A1 (en) 2017-04-18 2018-10-25 Celgene Quanticel Research, Inc. Therapeutic compounds
AR111479A1 (es) 2017-04-18 2019-07-17 Celgene Quanticel Res Inc Compuestos derivados de piridina y pirazol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130109652A1 (en) * 2004-09-17 2013-05-02 Addex Pharmaceuticals S.A. Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
US20090054434A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
WO2014055548A1 (en) * 2012-10-02 2014-04-10 Intermune, Inc. Anti-fibrotic pyridinones
WO2015058160A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors

Also Published As

Publication number Publication date
US20210205284A1 (en) 2021-07-08
US10617680B2 (en) 2020-04-14
JP2023088901A (ja) 2023-06-27
EP3612522A1 (en) 2020-02-26
US20200163946A1 (en) 2020-05-28
TW202332436A (zh) 2023-08-16
US20240293381A1 (en) 2024-09-05
TW201841900A (zh) 2018-12-01
EP3612522A4 (en) 2021-07-07
JP2020516672A (ja) 2020-06-11
WO2018195155A1 (en) 2018-10-25
US11890275B2 (en) 2024-02-06
US20180296543A1 (en) 2018-10-18
US11020380B2 (en) 2021-06-01

Similar Documents

Publication Publication Date Title
TWI788343B (zh) 治療用化合物
US11884680B2 (en) Bromodomain inhibitors
EP2049515B1 (en) Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis
US10336697B2 (en) Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors
TW201739744A (zh) 治療用化合物
JP2010505957A (ja) 糖尿病に対して使用されるｎ−アリールピラゾール化合物
KR20130062951A (ko) 키누레닌 생성 억제 작용을 갖는 함질소 복소환 화합물
KR20130130030A (ko) Vps34 억제제로서의 비-헤테로아릴 화합물
US20240247014A1 (en) Modulators of tnf-alpha activity
TW202041498A (zh) 抑制ｐｇｅ２／ｅｐ４信號傳導的化合物、其製備方法及其在醫藥上的應用
CN113272297B (zh) 作为h4拮抗剂化合物的吡唑衍生物
KR20210022646A (ko) 시아노트리아졸 화합물 및 이의 용도
US12521368B2 (en) Modulators of TNF-alpha activity
JP2025506446A (ja) 特定の化学物質、組成物、および方法
CN121311471A (zh) 异喹啉酮衍生物和4h-喹嗪酮衍生物以及其用于治疗疾病的药物组合物
HK1131134B (en) Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees